Post by
fox7mf on Feb 27, 2023 4:13am
PFE to acquire Seagen?
The WSJ is reporting that Pfizer is in early stage discussions to acquire Seagen for in and around $30b usd. I don't what, if any implications this holds for an Oncy deal, but certainly Pfizer only has so much money. Is Roche in the drivers seat to get a business development deal with Onc? Some answers Matt would be nice, Matt.
Comment by
fox7mf on Feb 27, 2023 4:28am
This certainly wasn't the first bit of news we were looking for at the end of PFE's 90 day exclusivity with Bracelet.
Comment by
Noteable on Feb 27, 2023 10:19am
Another advantage with the acquisition of ONCY is that Big Pharma, like Merck, Pfizer and Roche, would not face FTC and EU Competition Board secrutiny, as had Merck when they attempted to acquire Seagen last year for US$40 Billion.
Comment by
Noteable on Feb 27, 2023 10:58am
What this rumor does is to set the stage with the market, and its future expectations, for Pfizer to make multiple M&A deals this year for an accumulated value of US$40 Billion or more, without experiencing any negative reaction to the company's M&A moves.
Comment by
Lesalpes29 on Feb 27, 2023 11:05am
$25 billion in annual revenue by 2030 from business development deals, as it seeks to mitigate an expected $17 billion impact to the company’s annual revenue from drugs going off patent. Pfizer believes its acquisitions in 2022 brought the company 40% of the way to that $25 billion goal. Pfizer goal! $25 billion in annual revenue by 2030
Comment by
Noteable on Feb 27, 2023 11:44am
What th WSJ reported is that Seagen currently has a market cap of $30.14 billion and any acquisition agreement is expected to carry a heftier price tag than that. However it is unlikely that this acquiition will happen given that the regulators negative view of Merck's US$40 Billion offer for Seagen last year.